
    
      Data were recorded from patients suffering from familial hypercholesterolemia and treated by
      lipid apheresis using one of the two systems investigated for at least 3 months prior to
      inclusion in the study. Only those treatments were documented in which routine blood samples
      for laboratory analysis were taken, or in which adverse or serious adverse device effects
      occur.
    
  